PCA3 in Prostate Cancer

Roberta Gunelli; Eugenia Fragalà; Massimo Fiori

doi:10.1007/978-1-0716-1354-2_9

PCA3 in Prostate Cancer

Methods Mol Biol. 2021:2292:105-113. doi: 10.1007/978-1-0716-1354-2_9.

Authors

Roberta Gunelli¹, Eugenia Fragalà¹, Massimo Fiori²

Affiliations

¹ Department of Urology, GB Morgagni Hospital, Forlì, Italy.
² Department of Urology, GB Morgagni Hospital, Forlì, Italy. gunellifiori@gmail.com.

PMID: 33651355
DOI: 10.1007/978-1-0716-1354-2_9

Abstract

Prostate cancer antigen 3 (PCA3) is a urinary biomarker for prostate cancer and has demonstrated a good specificity and sensitivity representing a minimally invasive test.PCA3 assay could be useful in combination with PSA to suggest an eventual rebiopsy in men who have had one or more previous negative prostate biopsies.Combination of multiple tumor biomarkers will be the trend in the near future to achieve the goal of evaluate the aggressiveness of cancer and at the same time reducing the number of unnecessary biopsies.

Keywords: Biomarker; DD3; PCA3; Prostate Biopsy; Prostate Cancer.

MeSH terms

Antigens, Neoplasm / analysis*
Biomarkers, Tumor / analysis
Biopsy / methods
Humans
Male
Prostate / pathology*
Prostatic Neoplasms / diagnosis*

Substances

Antigens, Neoplasm
Biomarkers, Tumor
prostate cancer antigen 3, human